Log in

ABERA ABERA BIOSCIENCE AB NGM · Sweden

ABERA BIOSCIENCE AB (ABERA) news

ABERA BIOSCIENCE AB is a public biotech or pharmaceutical company listed on NGM under the ticker ABERA, recorded under Sweden. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest ABERA BIOSCIENCE AB news

We have not published a story on ABERA BIOSCIENCE AB yet. When there is news, it will appear here.

Questions about ABERA BIOSCIENCE AB

What is the ticker symbol of ABERA BIOSCIENCE AB?

ABERA BIOSCIENCE AB trades under the ticker ABERA on NGM.

Where is ABERA BIOSCIENCE AB listed?

ABERA BIOSCIENCE AB is listed on NGM.

Which country or territory is ABERA BIOSCIENCE AB listed under?

Our directory records ABERA BIOSCIENCE AB under Sweden.

What does ABERA BIOSCIENCE AB do?

Our directory classifies ABERA BIOSCIENCE AB as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of ABERA BIOSCIENCE AB?

The ISIN recorded for ABERA BIOSCIENCE AB is SE0015245097.

Does aibio.space cover ABERA BIOSCIENCE AB?

aibio.space lists ABERA BIOSCIENCE AB among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to ABERA BIOSCIENCE AB?

Companies in our directory listed in the same country and business area as ABERA BIOSCIENCE AB: Active Biotech AB, BICO Group AB, Vimian Group AB, NATTARO LABS AB, Magle Chemoswed Holding AB, Modus Therapeutics Holding AB.

Investor discussion: ABERA BIOSCIENCE AB

Members talk about ABERA BIOSCIENCE AB (ABERA). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NGM:ABERA on TradingView.

Listing details

ABERA BIOSCIENCE AB is a public biotech or pharmaceutical company listed on NGM under the ticker ABERA, recorded under Sweden. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
ABERA BIOSCIENCE AB
Ticker
ABERA
Listing
NGM
Country or territory
Sweden
Business scope
Biotechnology
ISIN
SE0015245097
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.